Call for action on rare disease

MSD has led a call for action to improve diagnosis and treatment of Pulmonary Arterial Hypertension across the Asia Pacific.

The Declaration for Action on Pulmonary Arterial Hypertension (PAH): Advancing Early Diagnosis, Equitable Access, and Societal Momentum was written with patient groups, healthcare providers, and non-government organisations across the region to pledge a shared commitment to strengthen PAH awareness, speed diagnosis, and improve care in the Asia Pacific, which accounts for around 60 per cent of all PAH deaths worldwide.

"As a company deeply committed to improving cardiovascular health, MSD Australia remains focused on closing the gaps in PAH awareness and ensuring the voices of people living with PAH are heard," MSD Australia & New Zealand Medical Director, Lilie Herawati, said.